Physician profile
Abdullah Tolaymat
NPI 1295022515
$4,956.60
in general payments reported to CMS, 2019-2025
29 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $1,515 · 2023: $905 · 2024: $1,133 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,034 · Education: $36.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,033.80 |
| Education | $36.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $836.10 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $789.80 | 2023-2025 | Fycompa |
| Ucb, INC. | $707.70 | 2021-2025 | Fintepla, Nayzilam, Briviact |
| Neurelis, INC. | $559.19 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $431.20 | 2022-2025 | |
| Corium, LLC | $389.26 | 2021-2025 | Azstarys |
| Biocodex, INC. | $208.84 | 2022-2025 | Diacomit |
| Eisai INC. | $207.41 | 2021-2022 | |
| Tris Pharma INC | $141.18 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Grt US Holding, INC. | $107.42 | 2022 | |
| Sunovion Pharmaceuticals INC. | $59.08 | 2022 | |
| Supernus Pharmaceuticals, INC. | $55.94 | 2022-2024 | Qelbree, Qelbree |
| Amneal Pharmaceuticals LLC | $47.37 | 2022-2023 | Lyvispah, Lioresal (Baclofen) |
| Ns Pharma, INC. | $38.84 | 2022 | |
| Acadia Pharmaceuticals INC | $35.92 | 2023 | Daybue |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $32.92 | 2021 | |
| Ptc Therapeutics, INC. | $31.47 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $31.08 | 2025 | Jornay Pm |
| Greenwich Biosciences, INC. | $29.70 | 2021 | |
| Ironshore Pharmaceuticals INC. | $28.18 | 2024 | |
| Biogen, INC. | $27.68 | 2022-2023 | Spinraza |
| Springworks Therapeutics, INC. | $26.75 | 2025 | Gomekli |
| Ultragenyx Pharmaceutical INC. | $23.18 | 2022 | |
| Octapharma USA, INC. | $22.97 | 2024 | Panzyga |
| Janssen Pharmaceuticals, INC | $22.39 | 2022 | |
| Medtronic, INC. | $19.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Tolaymat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.